Next-generation sequencing (NGS) technology can be used for rare and undiagnosed disease research to discover causative variants of inherited disorders by assessing many genes at the same time. Using NGS can reduce costs compared to traditional methods, which are often expensive and inconclusive while requiring extensive testing.
Of those, 80% have a genetic etiology, which may be uncovered with NGS and the TruSight One targeted panel.1-2 TruSight One is a targeted gene panel that uses NGS to simultaneously analyze up to 4813 genes associated with rare diseases.
Learn how the NextSeq 550 System is enhancing research in genetic health and why it’s being rapidly adopted in genetic testing labs. Get a glimpse into the advantages of this integrated, cost-effective solution for diverse applications, including rare disease research.View Video
From library prep, arrays, and sequencing to informatics, Illumina next-generation solutions empower researchers and clinicians across the globe to find the answers they seek in rare disease research.
We’re here with all the resources you need to accelerate progress. In addition to onsite training, ongoing support, and phone consults, we offer webinars and courses around the world.
Illumina offers cost-effective, streamlined, targeted NGS solutions that can empower your research into specific rare and undiagnosed diseases.
Perform NGS and cytogenomic array scanning all on one instrument with the NextSeq 550 System.
TruSight One Sequencing Panels target disease-associated regions of the exome with high analytical sensitivity and specificity.
The Illumina DRAGEN Bio-IT Platform facilitates rare disease research by enabling accurate, ultra-rapid secondary analysis of whole-genome and whole-exome sequencing data.3,4
Cardiologist Roger Foo established a rare disease research program using NGS to sequence babies with undiagnosed disease. This landmark NGS study led to a national clinical diagnostic exome sequencing platform in Singapore.Read Interview